A Phase II clinical trial demonstrates that SHEN26, a novel oral RNA-dependent RNA polymerase inhibitor, significantly reduces SARS-CoV-2 viral load in early-stage COVID-19 patients at 400mg dosage. The drug showed favorable safety profile with no serious adverse events, positioning it as a potential new treatment option for mild-to-moderate COVID-19 cases.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.